Deutsche Bank AG Has $291,000 Stake in Certara, Inc. (NASDAQ:CERT)

Deutsche Bank AG boosted its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 1,227.0% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 27,323 shares of the company's stock after buying an additional 25,264 shares during the period. Deutsche Bank AG's holdings in Certara were worth $291,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of CERT. D. E. Shaw & Co. Inc. raised its stake in shares of Certara by 77.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 77,665 shares of the company's stock valued at $827,000 after purchasing an additional 34,019 shares during the period. Daventry Group LP raised its stake in shares of Certara by 8.5% during the fourth quarter. Daventry Group LP now owns 1,642,053 shares of the company's stock valued at $17,488,000 after purchasing an additional 127,954 shares during the period. Bridgefront Capital LLC bought a new stake in shares of Certara in the fourth quarter worth $161,000. Bamco Inc. NY increased its stake in shares of Certara by 31.3% in the fourth quarter. Bamco Inc. NY now owns 315,000 shares of the company's stock worth $3,355,000 after buying an additional 75,000 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in shares of Certara in the fourth quarter worth $2,972,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Analyst Ratings Changes

CERT has been the subject of a number of research reports. Robert W. Baird lifted their price objective on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $11.00 to $14.00 in a research report on Thursday, May 8th. KeyCorp boosted their price target on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. TD Cowen initiated coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective on the stock. Finally, JMP Securities reissued a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Price Performance

Shares of CERT traded down $0.25 during trading hours on Thursday, hitting $11.70. The stock had a trading volume of 1,329,055 shares, compared to its average volume of 1,355,236. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.40. The company's fifty day moving average is $11.98 and its two-hundred day moving average is $11.82. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -58.50, a P/E/G ratio of 9.29 and a beta of 1.44.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. During the same period last year, the business earned $0.10 EPS. The business's quarterly revenue was up 9.7% on a year-over-year basis. On average, analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.